We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




3D Micro-Printed Sensors to Advance On-Chip Biosensing for Early Disease Detection

By LabMedica International staff writers
Posted on 06 Oct 2025

Early-stage disease diagnosis depends on the ability to detect biomarkers with exceptional sensitivity and precision. More...

However, traditional biosensing technologies struggle with achieving this at the micro-scale, especially when integrating multiple sensors into compact lab-on-a-chip systems. These limitations have slowed progress in creating real-time, low-cost diagnostic tools for early detection of diseases such as cancer and Alzheimer’s. Now, a new 3D micro-printed sensor offers a highly sensitive and scalable solution for on-chip biosensing to enable early disease detection.

Researchers at The Hong Kong Polytechnic University (PolyU, Hong Kong, China) have developed a 3D micro-printed Limacon-shaped whispering-gallery-mode (WGM) microlaser sensor that combines advanced optical resonance technology with flexible micro-printing. This innovation simplifies light coupling and boosts biosensing precision, marking a significant advance in lab-on-a-chip integration. The team leveraged PolyU’s state-of-the-art 3D micro-printing facilities to design and fabricate microcavity arrays with high speed and accuracy, overcoming long-standing technical barriers.

The microlaser sensor operates by circulating light resonantly within a microcavity where even minute molecular interactions cause detectable wavelength shifts. Conventional circular WGM sensors require fragile optical fibers to capture light, limiting their practicality. The new Limacon-shaped microdisk, however, achieves directional light emission and improved coupling efficiency without external fibers. Its hybrid rigid design provides a low lasing threshold and narrow linewidth, ensuring accurate detection even at ultra-low biomarker concentrations.

In experiments, the 3D WGM microlaser biosensors demonstrated outstanding performance, with a lasing threshold of only 3.87 μJ/mm2 and a linewidth of about 30 pm. The sensors successfully detected human immunoglobulin G (IgG) — a key antibody in blood — at concentrations as low as 70 ag/mL (attograms per milliliter). These results, published in Optics Letters, highlight the device’s capability for ultra-sensitive, label-free detection and its potential role in next-generation diagnostic systems.

The innovation not only enables precise detection but also paves the way for scalable fabrication of sensor arrays for real-time biomedical analysis. Future development will focus on integrating the microlaser sensors into microfluidic chips to create fully functional optofluidic biochips capable of simultaneously identifying multiple disease biomarkers. Such systems could enable rapid diagnosis at the point of care and provide critical insights during global health emergencies.

“In the future, these WGM microlaser sensors could be integrated into a microfluidic chip to enable a new generation of lab-on-a-chip devices for ultrasensitive, quantitative detection of multiple biomarkers,” said Professor Zhang A-ping, Department of Electrical and Electronic Engineering, The Hong Kong Polytechnic University. “This technology could be used for the early diagnosis of diseases such as cancers and Alzheimer’s disease, or for fighting major health crises such as the COVID-19 pandemic.”

Related Links:
PolyU


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Platelet Function Analyzer
PL-12
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.